REPLY: Shareholders’ Meeting approves the 2020 Financial Statements
26.4.2021 15:07:00 EEST | Business Wire | Press release
The General Shareholders’ meeting of Reply S.p.A. [MTA, STAR: REY] today approved the Financial Statements for the financial year 2020, confirming the distribution of a gross dividend of €0.56 per share.
The dividend will be paid on 5 May 2021, with dividend date set on 3 May 2021 (record date on 4 May 2021).
2020 Financial Statement
The Reply Group closed the 2020 financial year with a consolidated turnover of €1,250.2 million, recording a 5.7% increase compared to €1,182.5 million for the 2019 financial year.
Consolidated EBITDA was €207.9 million, up 8.7% compared to €191.3 million in 2019.
Consolidated EBIT, from January to December, was €169.5 million, up 9.1% compared to €155.3 million at December 2019.
The Group net profit was at €123.6 million, up 8.6% compared to €113.9 million recorded in 2019.
The Shareholders’ Meeting also approved the following resolutions, in accordance with the proposal of the Board of Directors:
Appointment of the Board of Directors and the Board of Statutory Auditors for the three-year period 2021-2023
The Shareholders’ Meeting appointed the new members to the Board of Directors and the Board of Statutory Auditors for the three-year period 2021-2023 based on the submitted list of candidates.
The following have been appointed as Directors:
- Mario Rizzante (Chairman), Tatiana Rizzante, Filippo Rizzante, Daniele Angelucci, Marco Cusinato, Elena Previtera and Patrizia Polliotto (who declared to comply with the independence requirements set forth in article 148 of the TUF [Testo unico sulla finanza – Financial Act] and the Corporate Governance Code), drawn from the majority list submitted by the shareholder Alika S.r.l. (holder of a 39.754% stake in Reply S.p.A.'s share capital), and obtained the highest number of votes (76.709% of votes obtained);
- Secondina Giulia Ravera and Francesco Umile Chiappetta, who declared to comply with the independence requirements set forth in article 148 of the TUF and the Corporate Governance Code, drawn from the minority list submitted by a group of investors (holding a total stake of 3.503% of Reply S.p.A.'s share capital).
The appointed Board of Statutory Auditors consists of three standing members and two alternates:
- Ciro Di Carluccio (Chairman) and Giancarla Branda (Alternate Auditor), who declared to comply with the independence requirements set forth in article 148 of the TUF and the Corporate Governance Code, drawn from the minority list submitted by a group of investors (holding a total stake of 3.503% of Reply S.p.A.'s share capital);
- Piergiorgio Re (Standing Auditor), Ada Garzino Demo (Standing Auditor), Stefano Barletta (Alternate Auditor), who declared to comply with the independence requirements set forth in article 148 of the TUF and the Corporate Governance Code, drawn from the majority list submitted by the shareholder Alika S.r.l. (holder of a 39.754% stake in Reply S.p.A.'s share capital), and obtained the highest number of votes (75.741% of votes obtained).
- The curricula vitae of the Directors and Statutory Auditors, as well as the additional documentation required by current legislation, are available in the investors’ section of the company website www.reply.com
Approval of the Programme for the Acquisition and/or Disposal of Own Shares
The Shareholders’ Meeting authorised a new share buyback programme, while withdrawing the current one approved at the Shareholders’ Meeting of 21 April 2020: the main objective of this programme is the purchase of shares to implement the stock incentive plans, transactions aimed at the acquisition of equity investments, extraordinary financial transactions and/or the conclusion of agreements with strategic partners.
The authorization has a duration of 18 months from the date of the resolution, for a maximum of 7,411,457 ordinary shares (equal to 19.8107% of the current share capital) with a nominal value of €0.13 each for a maximum nominal value of €963,489.41, within the limit of a maximum financial commitment of €300,000,000. The purchase price may not be lower than the nominal value (currently €0.13) and higher than the official trading price recorded on the MTA market on the day before the purchase, increased by 20%.
Approval of the Remuneration Report
The Shareholders' Meeting also approved Section II of the Remuneration Report drafted pursuant to Article 123-ter of Legislative Decree 58/1998.
Approval of the delegation of powers to the Board of Directors to increase the share capital with a share premium, subject to withdrawal of the previous delegation of powers granted on 21 April 2016
The Shareholders' Meeting withdrew the mandate conferred to the Board of Directors to increase the share capital, which expired on April 21, 2021, and reauthorized the Board of Directors, in compliance to article 2443 of the Italian Civil Code, to increase the share capital with a share premium and the exclusion of shareholders' option rights in compliance to article 2441, paragraph 4, up to a maximum nominal amount of 390,000.00 Euros through the issue of a maximum of 3,000,000 new Reply S.p.A. ordinary shares with a nominal value of 0.13 Euros each, to be executed in one or more tranches, therefore in a divisible manner, for a maximum period of five years, to be paid through contributions in kind of shares in other companies, having a similar or analogous purpose to the company's or in any case functional to the development of the business. The Shareholders' Meeting consequently resolved to amend Article 5 (Share Capital) of the Articles of Association
The manager in charge of drafting the company's financial reports, Dr Giuseppe Veneziano, declares in accordance with Paragraph 2 of Article 154-bis of the Consolidated Finance Act, that the accounting information contained in this press release corresponds to the company's records, ledgers and accounting records.
Reply
Reply [MTA, STAR: REY, ISIN: IT0005282865] specialises in the design and implementation of solutions based on new communication channels and digital media. Reply is a network of highly specialised companies supporting key European industrial groups operating in the telecom and media, industry and services, banking, insurance and public administration sectors in the definition and development of business models enabled for the new paradigms of AI, cloud computing, digital media and the Internet of Things. Reply services include: Consulting, System Integration and Digital Services www.reply.com
April 26, 2021
This press release is a translation, the Italian version will prevail.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210426005462/en/
Contact information
Media Contacts
Reply
Fabio Zappelli
f.zappelli@reply.com
Tel. +390117711594
Investor Relation Contacts
Reply
Riccardo Lodigiani
r.lodigiani@reply.com
Tel. +390117711594
Michael Lueckenkoetter
m.lueckenkoetter@reply.com
Tel. +49524150091017
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
FDA Issues Modified Risk Tobacco Product Orders for 20 ZYN Nicotine Pouch Products30.6.2026 19:19:00 EEST | Press release
Philip Morris International Inc. (PMI) (NYSE: PM) today announced that the U.S. Food and Drug Administration (FDA) issued Modified Risk Tobacco Product (MRTP) orders for 20 variants of ZYN nicotine pouch products. These are the first MRTP orders granted for nicotine pouches, allowing PMI U.S. to market the following claim for the authorized ZYN products: “Using ZYN instead of cigarettes puts you at a lower risk of mouth cancer, heart disease, lung cancer, stroke, emphysema, and chronic bronchitis.” “FDA’s decision is an important moment for the more than 45 million legal-age nicotine consumers in America,” saidStacey Kennedy, PMI U.S. CEO. “Today’s news ensures these adultshave access to accurate, science-based information, including FDA-authorized evidence that switching from cigarettes to ZYN reduces the risk of smoking-related diseases like heart disease and lung cancer,” she added. “More broadly, it reinforces the agency’s science-based approach to evaluating products across the co
Caidya Announces Strategic Combination with Simbec-Orion Bridging Early Scientific Insight and Global Clinical Execution30.6.2026 18:00:00 EEST | Press release
Caidya today announced a strategic combination with Simbec-Orion designed to close the divide between early scientific insight and global clinical execution. The combination of Caidya and Simbec-Orion creates a differentiated specialty clinical CRO platform that enables programs to scale, maintaining focus, speed, and accountability. The strategic combination brings together complementary strengths to create a more complete development partner for innovative biopharma companies. With established operations across Europe, the Americas, APAC, and China, the combined organization provides meaningful expertise and execution capabilities in the regions that matter most. Simbec-Orion brings early-phase clinical pharmacology capabilities alongside deep therapeutic expertise for later stage complex oncology and rare disease trials, helping sponsors shape critical decisions early in the development lifecycle. Together, the organizations strengthen their ability to support complex, cross-border
Archer® Proves Purpose-Built AI Beats General-Purpose LLMs on Regulatory Change Management: 95% Verified Accuracy, 80x Faster, 92% Lower Cost30.6.2026 17:13:00 EEST | Press release
For enterprises deploying AI in compliance, a wrong date is a missed deadline. The more dangerous failure is a wrong answer the model returns with high confidence, one that flows silently into a compliance calendar and is only discovered after the window has passed. Archer® today released results showing purpose-built AI beats a general-purpose large language model (LLM) on regulatory work, and it’s not close. This head-to-head test compared Archer’s purpose-built, vertical-specific AI and proprietary data sets against a leading general-purpose LLM, on a core compliance task: determining the publication, effective and comment-close dates of regulatory documents across six jurisdictions. General-purpose models are a genuine breakthrough, and this is no referendum on their quality. The question Archer set out to answer is narrower and more practical: what it takes to make a specific, high-stakes determination reliable, fast and affordable at scale. A vertical, domain-focused process, gro
Altasciences Supports Key Development Milestone for Steel Therapeutics’ Lead Therapeutic Candidate, Fizurex™30.6.2026 17:08:00 EEST | Press release
Altasciences, a leading drug development organization, today announced a significant milestone in the development of Steel Therapeutics, Inc.’s pivotal toxicology study for its lead product candidate, Fizurex™, for the treatment of anal fissures. The successful completion of the study plays a significant role in the advancement of Fizurex™ toward first-in-human trials. The GLP-compliant study demonstrated a favorable safety profile, which has advanced Steel Therapeutics' plans to submit an Investigational New Drug (IND) application for Fizurex™ to the FDA in Q3 2026. Fizurex™, a patent-pending, single-use topical wipe, was designed to provide a standardized, accessible treatment option for a painful and often undertreated medical condition. The product builds on years of use through compounding pharmacy prescriptions and is now advancing toward clinical development and regulatory review. "We are proud to have supported Steel Therapeutics with the generation of the high-quality safety d
Interactive Brokers Expands Access to Korean Equities with Launch of Nextrade ATS30.6.2026 17:00:00 EEST | Press release
Interactive Brokers (Nasdaq: IBKR), an automated global broker, today announced the launch of select Korean equities through Nextrade, South Korea's first Alternative Trading System (ATS). The addition of Nextrade builds on Interactive Brokers' earlier launch of the Korea Exchange (KRX), through which it became the first major US-based broker to provide global investors with direct access to Korean equities. Clients trading on Nextrade benefit from significantly extended trading hours and access to additional liquidity. Interactive Brokers has enabled IB SmartRouting℠ across both the Korea Exchange (KRX) and Nextrade, automatically routing orders to the venue offering the best price. This helps clients achieve best execution while providing greater flexibility and more opportunities to participate in one of Asia's most dynamic equity markets. Korea's equity market ranks among the top global exchanges by market capitalization and is home to world-leading companies such as Samsung Electr
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
